Background: Although anti-adhesion therapies are a novel mainstay in the treatment of inflammatory bowel diseases (IBDs), the mechanisms controlling integrin-dependent gut homing are poorly elucidated, and the available techniques for translational functional investigations are limited. Methods: We used dynamic adhesion assays to study adhesion of CD4+ T cells, CD8+ T cells, CD19+ B cells, and granulocytes to the addressins MAdCAM-1, VCAM-1, and ICAM-1. The effects of vedolizumab, natalizumab, etrolizumab-s, anti-CD11a, and anti-CD18 antibodies were explored. Results: Adhesion of peripheral blood leukocytes from IBD patients and control donors could be validly assessed, and integrin-mediated addressin adhesion could be specifically inhibited by anti-integrin antibodies. Numbers of adhering cells were partly, but not completely, related to integrin expression. Vedolizumab and etrolizumab-s resulted in similar reduction of adhesion to MAdCAM-1, and preliminary data proposed an association of dynamic adhesion to MAdCAM-1 with response to vedolizumab therapy. Conclusions: Dynamic adhesion assays are an easy and broadly applicable method for IBD research that is useful for future translational studies and potentially also for supporting clinical treatment decisions. 10.1093/ibd/izy077_video1izy077_Video_15786486962001.
Background: Although anti-adhesion therapies are a novel mainstay in the treatment of inflammatory bowel diseases (IBDs), the mechanisms controlling integrin-dependent gut homing are poorly elucidated, and the available techniques for translational functional investigations are limited. Methods: We used dynamic adhesion assays to study adhesion of CD4+ T cells, CD8+ T cells, CD19+ B cells, and granulocytes to the addressins MAdCAM-1, VCAM-1, and ICAM-1. The effects of vedolizumab, natalizumab, etrolizumab-s, anti-CD11a, and anti-CD18 antibodies were explored. Results: Adhesion of peripheral blood leukocytes from IBDpatients and control donors could be validly assessed, and integrin-mediated addressin adhesion could be specifically inhibited by anti-integrin antibodies. Numbers of adhering cells were partly, but not completely, related to integrin expression. Vedolizumab and etrolizumab-s resulted in similar reduction of adhesion to MAdCAM-1, and preliminary data proposed an association of dynamic adhesion to MAdCAM-1 with response to vedolizumab therapy. Conclusions: Dynamic adhesion assays are an easy and broadly applicable method for IBD research that is useful for future translational studies and potentially also for supporting clinical treatment decisions. 10.1093/ibd/izy077_video1izy077_Video_15786486962001.
Authors: Emily Becker; Sebastian Schramm; Marie-Theres Binder; Clarissa Allner; Maximilian Wiendl; Clemens Neufert; Imke Atreya; Markus Neurath; Sebastian Zundler Journal: J Vis Exp Date: 2018-09-20 Impact factor: 1.355
Authors: Sebastian Zundler; Claudia Günther; Andreas E Kremer; Mario M Zaiss; Veit Rothhammer; Markus F Neurath Journal: Nat Rev Gastroenterol Hepatol Date: 2022-08-09 Impact factor: 73.082
Authors: Laura Mühl; Emily Becker; Tanja M Müller; Raja Atreya; Imke Atreya; Markus F Neurath; Sebastian Zundler Journal: BMC Gastroenterol Date: 2021-01-22 Impact factor: 3.067
Authors: Michaela Melde; Tanja M Müller; Ines Schneider; Carol-Immanuel Geppert; Laura Mühl; Laura Besendorf; Clarissa Allner; Emily Becker; Imke Atreya; Francesco Vitali; Raja Atreya; Markus F Neurath; Sebastian Zundler Journal: Therap Adv Gastroenterol Date: 2021-11-24 Impact factor: 4.409
Authors: Laura Besendorf; Tanja M Müller; Carol-Immanuel Geppert; Ines Schneider; Laura Mühl; Imke Atreya; Francesco Vitali; Raja Atreya; Markus F Neurath; Sebastian Zundler Journal: Therap Adv Gastroenterol Date: 2022-06-28 Impact factor: 4.802
Authors: Clarissa Allner; Michaela Melde; Emily Becker; Friederike Fuchs; Laura Mühl; Entcho Klenske; Lisa Müller; Nadine Morgenstern; Konstantin Fietkau; Simon Hirschmann; Raja Atreya; Imke Atreya; Markus F Neurath; Sebastian Zundler Journal: BMC Gastroenterol Date: 2020-04-15 Impact factor: 3.067